๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Optical imaging approaches for molecularly-targeted drug discovery and development

โœ Scribed by Wafik S. El-Deiry


Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
98 KB
Volume
2
Category
Article
ISSN
1549-9634

No coin nor oath required. For personal study only.

โœฆ Synopsis


Nanomedicine is at the cutting edge of science, pushing the frontiers of chemistry, engineering, materials science, biochemistry, and molecular biology. Because the research and technology development are on the nanometer scale, small molecules are the most obvious tools to use to manipulate molecular events. In the Pharmacology Nanomedicine Symposium, we will present four talks that represent the newest advancements in drug discovery and delivery. In the first talk, Dr. Jeanne Hardy will discuss her approach to exploit allosteric sites on proteins for drug discovery. Dr. Wafik El-Deiry will discuss his development of imaging technology to monitor molecular events relevant to tumor progression and therapeutic response. Dr. Scott Diamond will present the strategies being used at the Penn Center for Molecular Discovery to develop microarrays and screens against proteases, kinases, and phosphatases on a nanoliter scale. The last talk of the session by Dr. David Needham will present a novel approach for drug delivery at sites of tumors using bnano-soccerballQ liposomes to control drug release temporally and spatially.


๐Ÿ“œ SIMILAR VOLUMES


Mouse Genetics/Genomics: An Effective Ap
โœ David B. West; Olga Iakougova; Christine Olsson; David Ross; Jeffrey Ohmen; Alu ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 540 KB

The mouse has become the premier mammalian system for the identification of the genetic basis of both mono-and oligogenic disorders, as well as the understanding of complex diseases with gene-gene and gene-environment interactions. The similarity between human and mouse genetic disease is sometimes

Targeting EGFR and HER-2 receptor tyrosi
โœ Shantaram Kamath; John K. Buolamwini ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 472 KB

Conventional anticancer therapy using cytotoxic drugs lacks selectivity and is prone to toxicity and drug resistance. Anticancer therapies targeting aberrant growth factor receptor signaling are gaining interest. The erbB receptor family belongs to the type I, the receptor tyrosine kinases class, an